{"member_organisations": "", "identification_number": "232923831740-31", "fields_of_interest": "Business and Industry, Public Health", "head_office_address": "Tomtebodav\u00e4gen 23A", "full_time_equivalent_fte": "0,25", "person_with_legal_responsibility": "Carin Dahlquist", "industry_forums": "", "grants": "", "country_code": "se", "inter_groups": "", "eu_initiatives": "Health policy, primarily those related with rare disease policy and access to medicines", "level_of_interest": "global", "organisation_name": "Swedish Orphan Biovitrum (Sobi)", "belgium_office_post_code": "", "number_of_persons_involved": "1", "person_in_charge_of_eu_relations": "Ana Palma", "section": "II - In-house lobbyists and trade/business/professional associations", "lon": "18.0228215", "source": "", "subsection": "Companies & groups", "belgium_office_phone": "(+32)28806119", "overall_budget_turnover_as_a_range": "", "belgium_office_address": "Rue Neerveld, 101-103", "persons_accredited_for_access_to_european_parliament_premises": "", "registration_date": "07/06/2018", "estimate_of_costs_absolute_amount": "", "website_address": "https://www.sobi.com/en", "commission_expert_groups_and_other_similar_entities_european_commission": "NA", "head_office_post_box": "", "head_office_city": "Stockholm", "membership": "Sobi is member of: \n- EuropaBio \n- EUCOPE", "head_office_post_code": "", "position": "Global HTA & Patient Access Lead BNL", "financial_year_start_date": "01/01/2017", "head_office_country": "Sweden", "number_of_ep_accredited_persons": "", "relevant_communication": "", "financial_year_end_date": "01/12/2017", "lat": "59.3501513", "estimate_of_costs_as_a_range": "50000-99999", "overall_budget_turnover_absolute_amount": "0", "legal_status": "SPRL", "procurement": "", "customers": "", "belgium_office_post_box": "", "goals__remit": "Sobi is a pharmaceutical company specialized in rare diseases. Our aim is to continue to develop rare disease treatments and to create access to those for patients. \n \nWe will continue to build on our strong position that covers the entire value chain for treatment of rare diseases in EMENAR and North America. Sobi offers an integrated process, from in-house research and development in protein characterisation, biologics manufacturing and industrialisation, to commercialisation of products for rare diseases. Partnering with stakeholders and facilitating effective and timely rare-disease therapy development, including an extensive and robust distribution network, creates unique opportunities for us to add value to the rare-disease field.", "belgium_office_city": "woluwe saint lambert", "head_office_phone": "(+46)86972000"}